Compare Stocks: ANIX, PRLD, CMPX, and RCKT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$2.76 +0.4%	$3.33	$2.32 ▼ $5.46	$93.56M	0.51	309,138 shs	389,132 shs
CMPX Compass Therapeutics	$2.00 -2.4%	$2.21	$1.61 ▼ $6.88	$369.18M	0.95	2.21 million shs	4.83 million shs
PRLD Prelude Therapeutics	$4.59 -1.7%	$5.06	$0.98 ▼ $6.83	$372.68M	0.97	529,716 shs	520,337 shs
RCKT Rocket Pharmaceuticals	$3.35 -3.7%	$3.57	$2.53 ▼ $5.45	$382.02M	0.5	1.23 million shs	1.66 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	+0.36%	-10.10%	-14.55%	+11.74%	-8.61%
CMPX Compass Therapeutics	-2.44%	-15.97%	-15.61%	-1.48%	-43.18%
PRLD Prelude Therapeutics	-1.71%	-15.93%	-19.90%	+2.23%	+285.71%
RCKT Rocket Pharmaceuticals	-3.74%	-13.21%	-1.76%	+21.82%	+5.35%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANIX Anixa Biosciences	$2.76 +0.4%	$3.33	$2.32 ▼ $5.46	$93.56M	0.51	309,138 shs	389,132 shs
CMPX Compass Therapeutics	$2.00 -2.4%	$2.21	$1.61 ▼ $6.88	$369.18M	0.95	2.21 million shs	4.83 million shs
PRLD Prelude Therapeutics	$4.59 -1.7%	$5.06	$0.98 ▼ $6.83	$372.68M	0.97	529,716 shs	520,337 shs
RCKT Rocket Pharmaceuticals	$3.35 -3.7%	$3.57	$2.53 ▼ $5.45	$382.02M	0.5	1.23 million shs	1.66 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANIX Anixa Biosciences	+0.36%	-10.10%	-14.55%	+11.74%	-8.61%
CMPX Compass Therapeutics	-2.44%	-15.97%	-15.61%	-1.48%	-43.18%
PRLD Prelude Therapeutics	-1.71%	-15.93%	-19.90%	+2.23%	+285.71%
RCKT Rocket Pharmaceuticals	-3.74%	-13.21%	-1.76%	+21.82%	+5.35%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANIX Anixa Biosciences	2.40	Hold	$10.00	262.32% Upside
CMPX Compass Therapeutics	2.88	Moderate Buy	$11.77	488.46% Upside
PRLD Prelude Therapeutics	2.40	Hold	$7.67	67.03% Upside
RCKT Rocket Pharmaceuticals	2.30	Hold	$8.57	155.86% Upside

Current Analyst Ratings Breakdown

Latest ANIX, PRLD, CMPX, and RCKT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/3/2026	ANIX Anixa Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/1/2026	RCKT Rocket Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$11.00
8/19/2026	ANIX Anixa Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/19/2026	ANIX Anixa Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2026	RCKT Rocket Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/11/2026	RCKT Rocket Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$16.00 ➝ $15.00
8/7/2026	CMPX Compass Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$4.00 ➝ $6.00
7/29/2026	PRLD Prelude Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/29/2026	PRLD Prelude Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$8.00
7/21/2026	ANIX Anixa Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/17/2026	CMPX Compass Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	$0.38 per share	N/A
CMPX Compass Therapeutics	$850K	423.74	N/A	N/A	$1.11 per share	1.80
PRLD Prelude Therapeutics	$22.42M	16.33	N/A	N/A	$1.09 per share	4.21
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	$2.56 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANIX Anixa Biosciences	-$10.93M	-$0.32	N/A	N/A	N/A	N/A	-76.59%	-67.80%	N/A
CMPX Compass Therapeutics	-$66.49M	-$0.40	N/A	N/A	N/A	N/A	-38.71%	-34.72%	11/4/2026 (Estimated)
PRLD Prelude Therapeutics	-$99.50M	-$0.73	N/A	N/A	N/A	N/A	-75.35%	-44.39%	11/11/2026 (Estimated)
RCKT Rocket Pharmaceuticals	-$223.12M	-$0.17	N/A	N/A	N/A	N/A	-52.77%	-44.92%	11/5/2026 (Estimated)

Latest ANIX, PRLD, CMPX, and RCKT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/9/2026	Q3 2026	ANIX Anixa Biosciences	-$0.0818	-$0.08	+$0.0018	-$0.08	N/A	N/A
8/11/2026	Q2 2026	PRLD Prelude Therapeutics	-$0.1967	-$0.14	+$0.0567	-$0.14	$5.70 million	$5.70 million
8/10/2026	Q2 2026	RCKT Rocket Pharmaceuticals	$0.86	$1.08	+$0.22	$1.08	$0.22 million	N/A
8/6/2026	Q2 2026	CMPX Compass Therapeutics	-$0.1107	-$0.13	-$0.0193	-$0.13	($0.60) million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANIX Anixa Biosciences	N/A	N/A	N/A	N/A	N/A
CMPX Compass Therapeutics	N/A	N/A	N/A	N/A	N/A
PRLD Prelude Therapeutics	N/A	N/A	N/A	N/A	N/A
RCKT Rocket Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANIX Anixa Biosciences	N/A	8.55	9.79
CMPX Compass Therapeutics	N/A	11.22	11.22
PRLD Prelude Therapeutics	N/A	4.07	4.07
RCKT Rocket Pharmaceuticals	0.05	9.24	9.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANIX Anixa Biosciences	29.13%
CMPX Compass Therapeutics	68.43%
PRLD Prelude Therapeutics	79.72%
RCKT Rocket Pharmaceuticals	98.39%

Insider Ownership

Company	Insider Ownership
ANIX Anixa Biosciences	26.40%
CMPX Compass Therapeutics	18.70%
PRLD Prelude Therapeutics	49.20%
RCKT Rocket Pharmaceuticals	21.30%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANIX Anixa Biosciences	5	34.02 million	25.04 million	Optionable
CMPX Compass Therapeutics	20	180.09 million	146.41 million	Not Optionable
PRLD Prelude Therapeutics	120	79.80 million	40.54 million	Optionable
RCKT Rocket Pharmaceuticals	240	109.78 million	86.39 million	Optionable

ANIX, PRLD, CMPX, and RCKT Headlines

Recent News About These Companies

Why Rocket Pharmaceuticals, Inc.’s (RCKT) Stock Is Down 5.03%

September 11 at 2:33 PM | aaii.comA

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Crosses Below 200 Day Moving Average - Here's What Happened

September 11 at 2:40 AM | americanbankingnews.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Stock Price Crosses Below 200-Day Moving Average - Should You Sell?

September 11 at 2:39 AM | marketbeat.com

Rocket Pharmaceuticals (RCKT) Up 6% Since Last Earnings Report: Can It Continue?

September 9 at 12:31 PM | zacks.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Coverage Initiated at Chardan Capital

September 3, 2026 | americanbankingnews.com

BlackRock Inc. Invests $33.94 Million in Rocket Pharmaceuticals, Inc. $RCKT

September 2, 2026 | marketbeat.com

Chardan Capital Reiterates "Buy" Rating for Rocket Pharmaceuticals (NASDAQ:RCKT)

September 1, 2026 | marketbeat.com

Ieq Capital LLC Invests $1.51 Million in Rocket Pharmaceuticals, Inc. $RCKT

August 27, 2026 | marketbeat.com

ADAR1 Capital Management LLC Makes New Investment in Rocket Pharmaceuticals, Inc. $RCKT

August 26, 2026 | marketbeat.com

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) Given Average Recommendation of "Hold" by Analysts

August 21, 2026 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Sells 3,493 Shares of Stock

August 18, 2026 | insidertrades.com

Rocket Pharmaceuticals' General Counsel Martin Wilson Sells Shares to Cover RSU Tax Obligations

August 17, 2026 | kalkinemedia.comK

Insider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) General Counsel Sells $11,806.34 in Stock

August 17, 2026 | marketbeat.com

Monaco Asset Management SAM Invests $8.48 Million in Rocket Pharmaceuticals, Inc. $RCKT

August 17, 2026 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Upgraded by Wall Street Zen to "Hold" Rating

August 17, 2026 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) Insider Sells 4,701 Shares

August 14, 2026 | insidertrades.com

Insider Selling: Rocket Pharmaceuticals (NASDAQ:RCKT) Insider Sells $16,453.50 in Stock

August 13, 2026 | marketbeat.com

Rocket Pharmaceuticals (NASDAQ:RCKT) COO Christopher James Stevens Sells 36,658 Shares of Stock

August 13, 2026 | marketbeat.com

Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus

August 11, 2026 | zacks.com

Rocket Pharmaceuticals: Q2 Earnings Snapshot

August 11, 2026 | aol.comA

Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial

August 3, 2026 | benzinga.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

ANIX, PRLD, CMPX, and RCKT Company Descriptions

Anixa Biosciences NASDAQ:ANIX

$2.76 +0.01 (+0.36%)

As of 09/11/2026 04:00 PM Eastern

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer. Its vaccine programs comprise the development of a vaccine against triple negative breast cancer; and a preventative vaccine against ovarian cancer. The company is also developing immuno-therapy drugs against cancer. The company was formerly known as ITUS Corporation and changed its name to Anixa Biosciences, Inc. in October 2018. Anixa Biosciences, Inc. was incorporated in 1982 and is based in San Jose, California.

Compass Therapeutics NASDAQ:CMPX

$2.00 -0.05 (-2.44%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$2.03 +0.03 (+1.50%)

As of 09/11/2026 07:58 PM Eastern

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

Prelude Therapeutics NASDAQ:PRLD

$4.59 -0.08 (-1.71%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$4.55 -0.04 (-0.96%)

As of 09/11/2026 07:57 PM Eastern

Prelude Therapeutics Incorporated, a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT1419, a myeloid cell leukemia-1 inhibitor, which is in Phase 1 clinical trial for the treatment of selected relapsed/refractory myeloid or B-cell malignancies; PRT2527, a cyclin-dependent kinase, which is in Phase 1 clinical trial for the treatment of advanced solid tumors; PRT3645, a cyclin-dependent kinase 4/6 inhibitor, which is in Phase 1 clinical trial for the treatment of advanced and metastatic solid tumors; and PRT3879, a SMARCA2 selective protein degrader, which is in Phase 2/3 clinical trial for the treatment of advanced and metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Rocket Pharmaceuticals NASDAQ:RCKT

$3.35 -0.13 (-3.74%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$3.33 -0.02 (-0.60%)

As of 09/11/2026 07:30 PM Eastern

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder that causes the immune system to malfunction; and pyruvate kinase deficiency, a rare red blood cell autosomal recessive disorder that results in chronic non-spherocytic hemolytic anemia. The company also has a clinical stage in vivo adeno-associated virus program for Danon disease, a multi-organ lysosomal-associated disorder leading to early death due to heart failure; Plakophilin-2 Arrhythmogenic Cardiomyopathy, an inheritable cardiac disorder; and BAG3 Dilated Cardiomyopathy. It has license agreements with Centro de Investigaciones Energéticas, Medioambientales y Tecnológicas, Centro de Investigacion Biomedica En Red, and Fundacion Instituto de investigacion Sanitaria Fundacion Jimenez Diaz; UCL Business PLC; The Regents of the University of California; and REGENXBIO, Inc. Rocket Pharmaceuticals, Inc. was founded in 1999 and is headquartered in Cranbury, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANIX, PRLD, CMPX, and RCKT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANIX, PRLD, CMPX, and RCKT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANIX, PRLD, CMPX, and RCKT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANIX, PRLD, CMPX, and RCKT Company Descriptions

Anixa Biosciences NASDAQ:ANIX

Compass Therapeutics NASDAQ:CMPX

Prelude Therapeutics NASDAQ:PRLD

Rocket Pharmaceuticals NASDAQ:RCKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ANIX, PRLD, CMPX, and RCKT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ANIX, PRLD, CMPX, and RCKT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ANIX, PRLD, CMPX, and RCKT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

ANIX, PRLD, CMPX, and RCKT Company Descriptions

Anixa Biosciences NASDAQ:ANIX

Compass Therapeutics NASDAQ:CMPX

Prelude Therapeutics NASDAQ:PRLD

Rocket Pharmaceuticals NASDAQ:RCKT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools